Table 2.
Cumulative virological responses in patients with chronic hepatitis B.
| Undetectable HBV-DNA (%) |
ETV (n = 66) | TDF (n = 30) | p |
|---|---|---|---|
| 4 weeks | 4.8% (3/66) | 0% (0/30) | 0.60 |
| 12 weeks | 34.8% (23/66) | 43.3% (13/30) | 0.43 |
| 24 weeks | 56.1% (37/66) | 63.3% (19/30) | 0.50 |
| 36 weeks | 69.7% (46/66) | 90% (27/30) | 0.03 |
| 48 weeks | 86.4% (57/66) | 96.7% (29/30) | 0.13 |
| 72 weeks | 93.9% (62/66) | 96.7% (29/30) | 0.58 |
| 96 weeks | 96.9% (63/65#) | 96.7% (29/30) | 0.58 |
TDF, tenofovir; ETV, entecavir; #one patient was excluded because of adding adefovir for the virological breakthrough.